Vecuronium

CHEMBL1201219 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
557.8 g/mol
LogP
6.5
Phase
4

This neuromuscular blocking agent is used during surgery or mechanical ventilation in hospitals to cause temporary paralysis of skeletal muscles, facilitating tracheal intubation and surgical procedures. It works by blocking the neuromuscular junction so that nerve signals cannot trigger muscle contractions. It has no pain-relieving or sedating properties and must always be used alongside appropriate anesthesia.

Молекулярная масса

557,8000 g/mol

LogP

6,50

TPSA

55,80 Ų

Правило пяти Липинского

Не соответствует

Терапевтические области

Механизм действия

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1

InChI

InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1

Molecular Formula

C34H57N2O4+

HBD / HBA

- / 5

Вращаемые Связи

6

Тяжёлые Атомы

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This neuromuscular blocking agent is used during surgery or mechanical ventilation in hospitals to cause temporary paralysis of skeletal muscles, facilitating tracheal intubation and surgical procedures. It works by blocking the neuromuscular junction so that nerve signals cannot trigger muscle contractions. It has no pain-relieving or sedating properties and must always be used alongside appropriate anesthesia.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Vecuronium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201219. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 39765. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.